Objective:To investigate the protocol and clinical efficacy of hair follicle-bearing microskin (HF-MS) transplantation in the treatment of hypertrophic scars.Methods:Prospective randomized controlled trial. From January to November 2024, patients with hypertrophic scars were recruited from the Medical Cosmetic Center of Affiliated Hangzhou First People’s Hospital with Westlake University School of Medicine and the Department of Plastic and Reconstructive Surgery of Ningbo Sixth Hospital. Patients were randomly divided into the observation group and the control group using a random number table. In the observation group, 1.0 mm punch decompression was performed on the hypertrophic scar area, followed by implantation of HF-MS extracted from the scalp donor site using follicular unit excision (FUE) into the decompression pores. The control group underwent only 1.0 mm punch decompression. Vancouver scar scale (VSS) scores (total score 0-15, higher scores indicating more severe scarring) were assessed preoperatively and at 1, 3, and 6 months postoperatively. Efficacy at 6 months, improvement in hypertrophic scar area, hair survival rate (observation group), adverse reactions, and patients’ satisfaction rates were evaluated. Categorical data were expressed as frequency (%) and analyzed using chi-square tests; normally distributed measurement data were expressed as Mean ± SD and analyzed using independent samples t-tests. Results:A total of 50 patients were included (25 per group), with 22 males and 28 females, aged 18-60 years (mean age: 33 years). The effective rate was 92% (23/25) in the observation group and 68% (17/25) in the control group, showing a statistically significant difference ( P<0.05). Preoperative VSS scores did not differ significantly between the observation and control groups [(6.67±3.19) vs. (7.12±2.89), P>0.05]. At 1, 3, and 6 months postoperatively, the observation group had VSS scores of (5.48±2.60), (4.64±2.39), and (3.80±2.10), respectively, compared to (6.36±2.53), (5.84±2.28), and (5.32±2.09) in the control group. The 6-month postoperative VSS scores differed significantly between groups ( P<0.05). Preoperative hypertrophic scar areas showed no significant difference [(5.75±2.83) cm 2 vs. (6.91±3.31) cm 2,P>0.05]. At 6 months postoperatively, the observation group had significantly smaller scar areas than the control group [(3.15±1.55) cm 2 vs. (5.37±2.93) cm 2,P<0.01]. The average hair survival rate in the observation group was 41% at 6 months. Adverse reactions occurred in 3 cases in the observation group (2 skin indurations, 1 hyperpigmentation) and 7 cases in the control group (4 hyperpigmentation, 2 skin atrophy, 1 skin induration). The observation group had a significantly lower adverse reaction rate [12% (3/25) vs. 28% (7/25), P<0.05]. Patient satisfaction rates were 88% (22/25) in the observation group and 64% (16/25) in the control group ( P<0.05). Conclusion:HF-MS transplantation demonstrates definitive clinical efficacy in treating hypertrophic scars, effectively improving scar morphology, clinical symptoms, and patient quality of life.

Objective:To investigate the protocol and clinical efficacy of hair follicle-bearing microskin (HF-MS) transplantation in the treatment of hypertrophic scars.Methods:Prospective randomized controlled trial. From January to November 2024, patients with hypertrophic scars were recruited from the Medical Cosmetic Center of Affiliated Hangzhou First People’s Hospital with Westlake University School of Medicine and the Department of Plastic and Reconstructive Surgery of Ningbo Sixth Hospital. Patients were randomly divided into the observation group and the control group using a random number table. In the observation group, 1.0 mm punch decompression was performed on the hypertrophic scar area, followed by implantation of HF-MS extracted from the scalp donor site using follicular unit excision (FUE) into the decompression pores. The control group underwent only 1.0 mm punch decompression. Vancouver scar scale (VSS) scores (total score 0-15, higher scores indicating more severe scarring) were assessed preoperatively and at 1, 3, and 6 months postoperatively. Efficacy at 6 months, improvement in hypertrophic scar area, hair survival rate (observation group), adverse reactions, and patients’ satisfaction rates were evaluated. Categorical data were expressed as frequency (%) and analyzed using chi-square tests; normally distributed measurement data were expressed as Mean ± SD and analyzed using independent samples t-tests. Results:A total of 50 patients were included (25 per group), with 22 males and 28 females, aged 18-60 years (mean age: 33 years). The effective rate was 92% (23/25) in the observation group and 68% (17/25) in the control group, showing a statistically significant difference ( P<0.05). Preoperative VSS scores did not differ significantly between the observation and control groups [(6.67±3.19) vs. (7.12±2.89), P>0.05]. At 1, 3, and 6 months postoperatively, the observation group had VSS scores of (5.48±2.60), (4.64±2.39), and (3.80±2.10), respectively, compared to (6.36±2.53), (5.84±2.28), and (5.32±2.09) in the control group. The 6-month postoperative VSS scores differed significantly between groups ( P<0.05). Preoperative hypertrophic scar areas showed no significant difference [(5.75±2.83) cm 2 vs. (6.91±3.31) cm 2,P>0.05]. At 6 months postoperatively, the observation group had significantly smaller scar areas than the control group [(3.15±1.55) cm 2 vs. (5.37±2.93) cm 2,P<0.01]. The average hair survival rate in the observation group was 41% at 6 months. Adverse reactions occurred in 3 cases in the observation group (2 skin indurations, 1 hyperpigmentation) and 7 cases in the control group (4 hyperpigmentation, 2 skin atrophy, 1 skin induration). The observation group had a significantly lower adverse reaction rate [12% (3/25) vs. 28% (7/25), P<0.05]. Patient satisfaction rates were 88% (22/25) in the observation group and 64% (16/25) in the control group ( P<0.05). Conclusion:HF-MS transplantation demonstrates definitive clinical efficacy in treating hypertrophic scars, effectively improving scar morphology, clinical symptoms, and patient quality of life.

A 62﹣year﹣old female patient received ramipril 2. 5 mg orally once daily for hypertension. About 12 hours after the first administration,the patient developed difficulty breathing,multiple skin rashes all over the body( mostly on chest and back,accompanied with itching),conjunctival hyperemia,lip swelling,oral mucosal hyperemia,pharyngeal congestion with pain,and etc. She was diagnosed with angioedema,which was considered to be caused by ramipril. Ramipril was stopped and anti﹣allergy treatments with adrenaline,promethazine hydrochloride,and dexamethasone were given. One hour later,the patient had improved symptoms and stable vital signs. On day 2 after the anti﹣allergy treatments,the patient had neither difficulty breathing nor new skin rash, and the anti﹣allergy drugs were replaced by methylprednisolone,calcium gluconate,and desloratadine cirate disodium. Antihypertensive treatment with levoamlodipine was also given. On day 3 after treatments,the patient′s skin rashes subsided with scars, congestion of the conjunctiva,oral mucosa,and pharynx relieved,and the lip swelling improved. On day 6 after treatments,the patient′s allergic symptoms completely disappeared,and her blood pressure was 122/78 mmHg.

A 62﹣year﹣old female patient received ramipril 2. 5 mg orally once daily for hypertension. About 12 hours after the first administration,the patient developed difficulty breathing,multiple skin rashes all over the body( mostly on chest and back,accompanied with itching),conjunctival hyperemia,lip swelling,oral mucosal hyperemia,pharyngeal congestion with pain,and etc. She was diagnosed with angioedema,which was considered to be caused by ramipril. Ramipril was stopped and anti﹣allergy treatments with adrenaline,promethazine hydrochloride,and dexamethasone were given. One hour later,the patient had improved symptoms and stable vital signs. On day 2 after the anti﹣allergy treatments,the patient had neither difficulty breathing nor new skin rash, and the anti﹣allergy drugs were replaced by methylprednisolone,calcium gluconate,and desloratadine cirate disodium. Antihypertensive treatment with levoamlodipine was also given. On day 3 after treatments,the patient′s skin rashes subsided with scars, congestion of the conjunctiva,oral mucosa,and pharynx relieved,and the lip swelling improved. On day 6 after treatments,the patient′s allergic symptoms completely disappeared,and her blood pressure was 122/78 mmHg.

Objective To observe the clinical efficacy of ozone injection combined with extracorporeal shock wave in treatment of arthritis of perishoulderr.Methods 120 patients with arthritis of perishoulderr and treated were choiced,they were randomly divided into two groups.Patients in group C were performanced extracorporeal shock wave treatment.Patients in group H were performanced with ozone injection combined with extracorporeal shock wave.Visu-al analogue score(VAS)and rane of motion(ROM)were used to evaluate the therapeutic effect.Results There was no significant difference between the two groups preoperation.Then significant difference of VAS in the two groups for 1week,1 month,3 months and 6 months after treatment showed respectively as (4.56 ±0.27)points vs.(2.49 ± 0.25)points,t =43.57,(3.96 ±0.23)points vs.(1.86 ±0.29)points,t =43.95,(3.36 ±0.20)points vs.(1.79 ± 0.25)points,t =36.51,(3.98 ±0.23)points vs.(2.09 ±0.27)points,t =41.29,P <0.05;The ROM data were respectively(55 ±18)points vs.(67 ±16)points,t =3.86,(60 ±20)points vs.(72 ±18)points,t =3.45,(56 ±19) points vs.(78 ±15),t =7.04,(46 ±18)points vs.(77 ±14)points,t =10.53,P <0.05.Patients feeled pain eased significantly in group H was significantly higher than group C in 6 month postoperativeiy.(χ2 =38.90,P <0.01;χ2 =8.91,P <0.05).Conclusion There is significant effect in patients with arthritis of perishoulderr treated by com-bined ozone injection with extracorporeal shock wave.

Objective To explore the influence of social support on compliance of respiratory function exercise and rehabilitation in patients with coronary artery bypass graft surgery. Methods A total of 102 patients with coronary artery bypass graft surgery were evaluated by General Data Survey Scale,Social Support Questionnaire and Compliance of Respiratory Function Exercise Scale.According to the situation of patients′social support, patients were divided into high score group,medium score group and low score group, then compliance of respiratory function exercise,postoperative ICU stay time, postoperative ventilation time, postoperative hospital stay, 6-min walking test (6MWD) and left ventricular ejection fraction (LVEF) were compared among three groups. Results The social support of patients with coronary artery bypass graft surgery in medium level,the score was (34.70 ±7.46) points. The postoperative ventilation time, postoperative ICU stay time in high score group were less than those in medium score group and low score group:(17.79±5.30) h vs. (42.41±14.18), (80.00±11.15) h, (24.29±6.00) h vs. (55.66±16.31), (92.46±10.21) h, and there were significant differences, F=47.340,110.252,P<0.01. The compliance of respiratory function exercise,6MWD and LVEF in high score group were better than those in medium score group and low score group:(38.93±24.37) points vs.(30.26±4.79), (19.85±4.45) points, (376.07±55.92) m vs. (328.83±59.27), (302.04±60.24) m, (60±4)%vs. (53±9)%, (51±10)%, and there were significant differences, F=286.040, 55.228, 20.159,P < 0.01. Conclusions Social support can improve the patients′adherence to treatment, and enhance the patients′ability to cope with stressful events,then accelerate the process of postoperative rehabilitation of patients effectively,and improve quality of life.

This study was aimed to explore brain regions which were closely related to the disease onset of premenstrual syndrome (PMS) with liver-qi depression. The BOLD-functional magnetic resonance imaging (fMRI) was used in the study. The processing of imaging data was based on the SPM 8 software and the REST software of the matlab platform. Each cluster was more than 389 continuous voxel. The brain region with single voxel of P < 0.05 (corrected) was defined as region with statistical significance. The 2 Sample T-Test was applied in the case group and the control group. The results showed that compared with the normal control group, the frontal lobe, occipital lobe, insula, limbic lobe, basal nuclei, and cingulate gyrus were activated in the PMS with liver-qi depression cases. It was concluded that the disease onset of PMS with liver-qi depression cases was related to brain regions such as frontal lobe, occipital lobe, insula, limbic lobe, basal nuclei, and cingulate gyrus.